Sign In
Buy 0J8P
Idexx Laboratories Earnings Calls
| Release date | Nov 03, 2025 |
| EPS estimate | $3.14 |
| EPS actual | $3.40 |
| EPS Surprise | 8.28% |
| Revenue estimate | 1.067B |
| Revenue actual | 1.105B |
| Revenue Surprise | 3.61% |
| Release date | Aug 04, 2025 |
| EPS estimate | $3.30 |
| EPS actual | $3.63 |
| EPS Surprise | 10.00% |
| Revenue estimate | 1.059B |
| Revenue actual | 1.109B |
| Revenue Surprise | 4.75% |
| Release date | May 01, 2025 |
| EPS estimate | $2.85 |
| EPS actual | $2.96 |
| EPS Surprise | 3.86% |
| Revenue estimate | 1.06B |
| Revenue actual | 998.427M |
| Revenue Surprise | -5.83% |
| Release date | Feb 03, 2025 |
| EPS estimate | $2.40 |
| EPS actual | $2.62 |
| EPS Surprise | 9.17% |
| Revenue estimate | 1.003B |
| Revenue actual | 954.288M |
| Revenue Surprise | -4.88% |
Last 4 Quarters for Idexx Laboratories
Below you can see how 0J8P.L performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 03, 2025 |
| Price on release | $469.99 |
| EPS estimate | $2.40 |
| EPS actual | $2.62 |
| EPS surprise | 9.17% |
| Date | Price |
|---|---|
| Jan 28, 2025 | $420.66 |
| Jan 29, 2025 | $416.00 |
| Jan 30, 2025 | $427.72 |
| Jan 31, 2025 | $424.51 |
| Feb 03, 2025 | $469.99 |
| Feb 04, 2025 | $464.23 |
| Feb 05, 2025 | $463.07 |
| Feb 06, 2025 | $461.54 |
| Feb 07, 2025 | $463.41 |
| 4 days before | 11.73% |
| 4 days after | -1.40% |
| On release day | -1.22% |
| Change in period | 10.16% |
| Release date | May 01, 2025 |
| Price on release | $470.25 |
| EPS estimate | $2.85 |
| EPS actual | $2.96 |
| EPS surprise | 3.86% |
| Date | Price |
|---|---|
| Apr 25, 2025 | $437.00 |
| Apr 28, 2025 | $430.53 |
| Apr 29, 2025 | $435.32 |
| Apr 30, 2025 | $432.14 |
| May 01, 2025 | $470.25 |
| May 02, 2025 | $472.31 |
| May 05, 2025 | $468.39 |
| May 06, 2025 | $475.02 |
| May 07, 2025 | $482.60 |
| 4 days before | 7.61% |
| 4 days after | 2.63% |
| On release day | 0.438% |
| Change in period | 10.43% |
| Release date | Aug 04, 2025 |
| Price on release | $649.50 |
| EPS estimate | $3.30 |
| EPS actual | $3.63 |
| EPS surprise | 10.00% |
| Date | Price |
|---|---|
| Jul 29, 2025 | $571.89 |
| Jul 30, 2025 | $577.62 |
| Jul 31, 2025 | $545.64 |
| Aug 01, 2025 | $532.28 |
| Aug 04, 2025 | $649.50 |
| Aug 05, 2025 | $644.22 |
| Aug 06, 2025 | $634.37 |
| Aug 07, 2025 | $640.01 |
| Aug 08, 2025 | $650.44 |
| 4 days before | 13.57% |
| 4 days after | 0.145% |
| On release day | -0.81% |
| Change in period | 13.74% |
| Release date | Nov 03, 2025 |
| Price on release | $721.70 |
| EPS estimate | $3.14 |
| EPS actual | $3.40 |
| EPS surprise | 8.28% |
| Date | Price |
|---|---|
| Oct 28, 2025 | $640.84 |
| Oct 29, 2025 | $630.37 |
| Oct 30, 2025 | $629.93 |
| Oct 31, 2025 | $634.14 |
| Nov 03, 2025 | $721.70 |
| Nov 04, 2025 | $721.00 |
| Nov 05, 2025 | $708.23 |
| Nov 06, 2025 | $696.42 |
| Nov 07, 2025 | $707.89 |
| 4 days before | 12.62% |
| 4 days after | -1.91% |
| On release day | -0.0970% |
| Change in period | 10.46% |
Idexx Laboratories Earnings Call Transcript Summary of Q3 2025
IDEXX reported a strong Q3 2025: revenue +13% reported and +12% organic, led by Companion Animal Group (CAG) diagnostics recurring revenue (+10% organic) and a 71% organic increase in instrument revenues driven by InVue Dx placements. Management raised full-year revenue guidance by ~$43 million at the midpoint to $4.270–4.300 billion and increased EPS guidance to $12.81–$13.01 (12%–14% comparable EPS growth). Gross margin expanded ~80 bps (to 61.8%), comparable operating margin improved ~120 bps, and Q3 EPS was $3.40. Free cash flow was $371 million in Q3 and $964 million TTM, with conversion targeted at 95%–100% of net income for the year; the company repurchased $242 million of stock in Q3 ($985 million YTD). Key commercial/innovation highlights: ~5,665 premium instrument placements in Q3 (InVue Dx placements of 1,753 in the quarter; >4,400 YTD), updated 2025 InVue placement target of ~6,000, nearly 5,000 customers for Cancer Dx, and rapid adoption of Catalyst Cortisol. Management is investing in commercial expansion (including adding sales coverage in three international countries by early 2026) and R&D (continued instrument, biomarker and software development) while maintaining a strong balance sheet (net leverage ~0.5x).
